spacer
home > epc > autumn 2017 > ethical approaches
PUBLICATIONS
European Pharmaceutical Contractor

Ethical Approaches

Despite the continuous development of new treatments, availability of efficient and safe methods remains a great unmet need. This term, ‘methods’, refers to the vast range of approaches to chemical and biologic medications, cell-based therapies, medical devices, psychotherapy and so on. Testing new procedures against placebo is thought to provide the most reliable data on the value of a new solution.

However, it is not unusual that this comparison is unfeasible for technical or practical reasons or because it is considered unethical. The latter especially affects the development of treatments for severe diseases or for vulnerable populations, where the use of a placebo instead of an active comparator or standard-of-care may be dangerous for the subject. In some cases, the use of placebos can also be linked with a risk to other people, for example, due to an increased possibility of aggressive or asocial behaviours.

These considerations have fuelled many years of debate over the use of placebos in clinical trials. Regulators, opinion leaders, patient advocates and journalists express their opinions on this matter – noticing a disagreement between the stakeholders is easy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Piotr Piotrowski is a Medical Director at KCR and holds a PhD in neurology. He is responsible for cross-therapeutic oversight of new and ongoing company projects from a medical perspective. Piotr’s professional experience includes more than 10 years in medical affairs, preclinical research, clinical development and regulatory affairs in the environment of the world’s top pharma industry and academic entities.

Dr Magdalena Czarnecka is a member of the Commercial Project Support Team at KCR, responsible for landscaping and development of clinical documentation. She gathered her professional experience during preclinical research at Georgetown University in Washington DC, US, and her work for a consulting firm focused on medical technology assessment. Magdalena holds a PhD in physiology and biophysics.

Dr Anna Baran
is a Chief Medical Officer at KCR. She leads the organisation’s early stages of study operations and provides cross-functional support to all service areas, ensuring the smooth integration of medical affairs and regulatory and business development efforts. Throughout her career, Anna has worked closely with recognised authorities across Eastern Europe and has been involved in developing national legislation for clinical trials registration.
spacer
Dr Piotr Piotrowsk
spacer
spacer
spacer
Dr Magdalena Czarnecka
spacer
spacer
spacer
Dr Anna Baran
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IONTAS to Generate Antibodies using Mammalian Display Technology for a Global Biopharma

Cambridge, UK, 22 January 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it has signed an agreement with Sanofi to discover antibodies using IONTAS’ proprietary Mammalian Display Technology.
More info >>

White Papers

Mauritius Island – An Emerging Centre for R&D in Biotechnology and the Life Sciences

CIDP (Centre International de Développement Pharmaceutique)

Mauritius, the tropical island situated in the Indian Ocean and known worldwide for its beautiful beaches, is also internationally recognised for its rule of law, and political and social stability. Over the past few years, the economy has been successfully transitioned from a monocrop to a diversified innovation-driven and knowledge-based economy, resting on agribusiness, export-oriented manufacturing, tourism, financial services, property development and real estate, ICT-BPO, the seafood industry, a free port, logistics and a nascent ocean economy. Emerging sectors such as healthcare and life sciences are presenting some niche areas for the taking, and the enabling environment is being put in place to make it happen - especially in the light of sustained growth within pharmaceutical, medical device, and clinical research. Important international players are already in operation locally as the country has established the appropriate legal and regulatory frameworks based on international norms, for the development of a strong biomedical research sector.
More info >>

 
Industry Events

5th Annual Peptides Congress 2018

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our highly anticipated 5th Annual Peptides Congress, 16th– 17th April 2018, London, UK. Over 450 peptides, proteins and antibodies attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement